The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) who purchased shares between December 14, 2017 and August 7, 2018. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws.
In particular, the Ampio lawsuit alleges that (1) the FDA would find Ampio's AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants' public statements were materially false and misleading at all relevant times.
Shareholders have until October 24, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >